An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension.
Phase of Trial: Phase III
Latest Information Update: 10 Apr 2014
At a glance
- Drugs Amlodipine/telmisartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 29 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Apr 2011 Planned end date changed from 1 May 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.